Eli Lilly gets FDA approval for new migraine drug
Eli Lilly and Company (LLY) is up 0.1% Friday morning. The company announced the U.S. Food and Drug Administration approved its new migraine drug Emgality. The drug is expected to sell for $575 a month, in-line with two other new drugs that are on the market.
Eli Lilly and Company (LLY) is a drug manufacturer.
Lowe’s Companies, Inc. (LOW) and The Boeing Company (BA) top the list of other companies with positive news today, while Tesla, Inc. (TSLA) and Applied Optoelectronics, Inc. (AAOI) top the list of companies with negative news.
Already a member?
Login to see your Morning News Leader Trade Idea.
Not yet a member?
You can receive four timely bull-put credit spreads each market day by joining our InvestorsKeyhole Daily Trade Alerts Service. Our analysts scour the news looking for unusual options activity, how insiders are trading, and breaking news, and publish trades accordingly.
Become A Member
About Eli Lilly and Company
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.